A novel GLP-1and FGF21 fusion protein for the treatment of non-alcoholic steatohepatitis (NASH)
HSP763-01 exhibited a clear dual target of GLP-1 and FGF21, which has been demonstrated by a robust response to the HFD/CCl<sub>4</sub> model, showing a marked improvement in lipid metabolism, lowering of blood glucose, weight loss, significant alleviation of liver steatosis, ballooning, and partial relief of lobular inflammation and fibrosis.
Authors
- Zhipeng Zhang (ORCID: https://orcid.org/0009-0005-4922-7630)
- Yuan Miao (ORCID: https://orcid.org/0000-0003-2086-1900)
- Cheng Xie (ORCID: https://orcid.org/0000-0001-9270-4213)
- Xiaomei Zhang (ORCID: https://orcid.org/0000-0002-0510-6352)
- Dong Wang (ORCID: https://orcid.org/0000-0002-3154-5471)
- Yan He (ORCID: https://orcid.org/0009-0001-6484-6537)
- Yanqin Ma
- Huaien Song
Institutions
- Jiangnan University (CN)
- WuXi AppTec (China) (CN)
- Jiangsu T-mab BioPharma (China) (CN)
Publication Details
- Journal
- Advanced Pharmaceutical Bulletin
- Published
- 2024-12-10
- DOI
- https://doi.org/10.34172/apb.43672
- Citations
- 1
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 0.23